DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$73.37
1.83 (2.56%)
▲
5d:
-3.07%
30d:
+6.88%
90d:
+19.17%
BUY
MODERATE Confidence
Analysis Updated: Jul 27, 2026 12:00 AM ET
Earnings: Jul 30, 2026
1d
Smart Money Accumulation
None View Scanner →
Strength: 4.8/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DXCM shows positive signals but monitor for confirmation. Market pricing in 0.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: DXCM shows positive signals but monitor for confirmation. Market pricing in 0.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$126.82
Based on 11.5% avg growth
INTRINSIC VALUE TODAY
$78.74
6.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $73.37, which is considered fair relative to its 30-day fair value range of $69.54 to $75.03. The stock's valuation (Forward PE: 23.8) is in line with its historical norms (24.1). Remarkably, the market is currently pricing in an annual earnings decline of 0.4% over the next few years. This pessimistic expectation contrasts with the company's recent 92.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DXCM is in a uptrend. Immediate support is located at $69.79, while resistance sits at $79.15.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $86.12 (+17.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DXCM is in a uptrend. Immediate support is located at $69.79, while resistance sits at $79.15.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $86.12 (+17.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$69.54 -
$75.03
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($86.12)
Trading Range Analysis
30-Day Trading Range
$69.54 -
$75.03
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$69.79
Resistance Level
$79.15
Current Trend
Uptrend
Technical data as of
Jul 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.84
Wall Street Target
$86.12
(+17.4%)
Revenue Growth (YoY)
15.0%
Earnings Growth (YoY)
92.2%
Profit Margin
19.3%
Valuation Discount vs History
-0.4% cheaper
PE vs Historical
23.8 vs 24.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.4%
(market-implied from PE analysis)
1-Year Target
$73.08
(0%)
2-Year Target
$72.78
(-1%)
3-Year Target
$72.49
(-1%)
3-Yr Target (if PE normalizes)
(PE: 24→24)
$73.28
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.8, Growth: 18.9%)
$123.23
(+68%)
Base:
(SPY PE: 20.8, Growth: 18.9%)
$107.56
(+47%)
Bear:
(PE: 17.7, Growth: 18.9%)
$91.43
(+25%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 30.70 | Current EPS (TTM): $2.33
Bull Case
$103.94
(+42%)
Analyst growth 32.1%, PE expands to 33.8
Base Case
$94.49
(+29%)
Market implied 32.1%, PE stable at 30.7
Bear Case
$48.65
(-34%)
Severe decline -20.0%, PE contracts to 26.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.8 to 24.1
Stabilization Target:
$74.17
(+1.1%)
PE Expansion Potential:
+1.1%
Share & Embed Analysis
Last updated: July 28, 2026 3:14 AM ET
Data refreshes hourly during market hours. Next update: 4:14 AM
Data refreshes hourly during market hours. Next update: 4:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
1
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$72 | 52 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 49 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$238 | 53 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 53 HOLD |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
